Related Experiment Video
Updated: Oct 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series
Laure Frechet1, Eve Puzenat1, Romain Charollais1
1Dpt of Dermatology and Inserm Unit 1098 RIGHT, University of Franche Comté and University Hospital, Besançon, France.
Background:
Dissecting cellulitis of the scalp (DCS), also known as Hoffmann disease or perifolliculitis capitis abscedens et suffodiens, is a rare disease characterized by chronic inflammation of the scalp. Treatment is difficult and often disappointing.
Objectives:
To report our experience of TNF inhibitors in a series of patients with DCS.
Materials & Methods:
We conducted a monocentric retrospective study of nine patients with DCS treated with TNF blocker after failure of other conventional treatments.
Results:
After a mean duration of treatment by TNF inhibitors of 17 ± 16 months, four patients (44% versus 0%) had a Physician's Global Assessment score of 0 or 1. We observed a 67% reduction in the number of inflammatory nodules, an 88% reduction in purulent drainage and a 45% improvement in Dermatology Life Quality Index. The mean treatment satisfaction index was 6.6 ± 1.6 out of 10.
Conclusion:
Our study suggests that TNF inhibitors are effective against disease activity and may improve quality of life in the management of DCS refractory to conventional treatments.
Related Concept Videos
The Tumor Microenvironment
Acne Infection

